CMV Cytotoxic T-Lymphocytes

Phase 2Biologic

NNew York Medical College

CMV Cytotoxic T-Lymphocytes is one of 2 biologic programs targeting CMV Infection. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

CMV InfectionRecruiting

CMV InfectionPhase 2

Recruiting

Competition

Competitive Landscape

1 competitor in CMV Infection

#DrugCompanyPhaseTrials

Artesunate

AAmivas Inc.

Phase 2

1 2

CMV Cytotoxic T-Lymphocytes

NNew York Medical College

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Recruiting

CMV Infection

NCT05564598

Clinical

Trials by Indication[1]

CMV Infection1 trial

CMV CTLs in Neonates With CMV Infection

Recruiting·NNew York Medical College·Phase 2·NCT05564598·23 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CMV Cytotoxic T-Lymphocytes. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CMV Cytotoxic T-Lymphocytes compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CMV Cytotoxic T-Lymphocytes. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — New York Medical College company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: NNew York Medical College

CMV Cytotoxic T-Lymphocytes

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

CMV Infection1 trial

References

Drug Info

Quick Facts

Related News